Revvity, Inc. provides products, services, and solutions to the diagnostics, life sciences, and applied services markets globally. The company is headquartered in Waltham, Massachusetts.
| Revenue (TTM) | $2.91B |
| Gross Profit (TTM) | $1.60B |
| EBITDA | $875.83M |
| Operating Margin | 17.10% |
| Return on Equity | 3.21% |
| Return on Assets | 2.37% |
| Revenue/Share (TTM) | $25.77 |
| Book Value | $64.78 |
| Price-to-Book | 2.19 |
| Price-to-Sales (TTM) | 5.85 |
| EV/Revenue | 6.24 |
| EV/EBITDA | 23.54 |
| Quarterly Earnings Growth (YoY) | 1.20% |
| Quarterly Revenue Growth (YoY) | 1.30% |
| Shares Outstanding | $111.59M |
| Float | $102.49M |
| % Insiders | 0.26% |
| % Institutions | 103.66% |
Volatility is currently contracting
.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will host its 2026 Investor Day on Friday, November 13 at 9:00 a.m. ET.Presentations from members of Revvity's senior management team will provide updates on the Company's key business initiatives, operational achievements and financial outlook.To register for the Investor Day webcast, visit here. A replay of the webcast and all presentations will be available on the Events page of the Revvity Investor Relations webs.
Revvity (RVTY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced that it will release its third quarter 2026 financial results prior to market open on Tuesday, November 3, 2026. The Company will host a conference call the same day at 7:30 a.m. ET to discuss these results. Prahlad Singh, president and chief executive officer, and Max Krakowiak, chief financial officer, will host the conference call. To access the call, a live audio webcast will be available on the Investors section o.
RVTY's diagnostics growth, AI-driven demand and life sciences expansion support its outlook, though China and margin pressures pose near-term challenges.
Revvity launches a CE-IVDR-certified automated T1D screening kit for children, expanding its GSP platform from newborn screening into early childhood.
WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) today announced the launch of the GSP® T1D 3plex kit, a fully automated, CE-IVDR-certified, multiplex autoantibody (AAb) detection solution to enable population-wide screening programs that identify children at risk of developing type 1 diabetes (T1D) before symptoms appear. A critical public health challenge, T1D is often only identified after significant beta-cell damage has occurred, presenting first as a life-threatening diabetic k.
Revvity (RVTY) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Revvity, Inc. (RVTY) Presents at 2026 Global Healthcare Conference Transcript
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on RVTY and any ticker you trade — then tracks every position and per-strategy win rate.
